T-cell　acute　lymphocytic　leukemia　(T-ALL)　is　the　most　common　cancer　in　children,　with　a　low　survival　rate　because　of　drug　resistance　and　a　high　recurrence　rate.　Targeted　delivery　of　chemotherapy　drugs　can　reduce　their　side　effects　and　improve　their　efficacy.　The　abnormality　of　phosphatidylinositol-3-kinase/protein　kinase　B/　mammalian　target　of　rapamycin　(PI3K/Akt/mTOR)　pathway　plays　a　key　role　in　T-ALL　occurrence.　AZD5363　is　a　selective　Akt　inhibitor　with　promising　therapeutic　potential　for　tumors　encoded　by　the　PI3K/Akt/mTOR　pathway.　However,　the　toxicity　and　side　effects　have　limited　its　application　in　treating　T-ALL.　This　study　aimed　to　design　a　delivery　system　for　targeting　AZD5363　to　T-ALL　by　sgc8c　aptamer　designed　as　mesoporous　silica　(mSiO2)　decorated　with　Au　nanoparticles.　The　cell-specific　targeting　and　cytotoxicity　of　mSiO2-Au-AZD5363-Apt　were　investigated.　The　mSiO2-Au　nanovehicles　were　found　feasible　for　AZD5363　delivery,　with　high　loading　efficiency　and　pH-responsive　release　in　the　acidic　lysosome.　More　importantly,　mSiO2-Au-AZD5363-Apt　nanovehicles　could　specifically　recognize　and　enter　T-ALL　cells　in　vitro　and　in　vivo,　effectively　inhibiting　the　proliferation　of　CCRF-CEM　cells.　In　conclusion,　mSiO2-Au-AZD5363-Apt　provided　an　effective　therapeutic　method　for　the　targeted　treatment　of　T-ALL.　©　2023　The　Authors